Anhui Poly Pharm Co., Ltd. is a wholly-owned subsidiary of Hainan Poly Pharm Co. Ltd., dedicated to the pharmaceutical industry with a focus on the production of Active Pharmaceutical Ingredients (APIs). Established in 2018, the company has implemented stringent GMP quality systems that comply with both US and EU standards. Currently, Anhui Poly Pharm operates three API production workshops, encompassing ten production lines and 357 multi-functional pieces of equipment. In 2023, their production lines for Gadoterate Meglumine and Cyclophosphamide successfully passed the FDA on-site inspection. The company has also launched the production of three MRI contrast agents, alongside validation batches of Semaglutide and various antitumor products.

Services include:
- APIs (Active Pharmaceutical Ingredients)
- Contract Development and Manufacturing (CDMO)
- 505(b)(2)
- Biosimilars
- Chemistry (CMC)
- Manufacturing
- Contract Manufacturing (CMO)
- Contract Packaging
- Contract Research (CRO)
- Contract Sales
- Distribution
- Creams & Ointments
- Dose Form
- Sterile
- Injectables
- Liquids
- Lyophilization
- Parenterals
- Large Volume

Anhui Poly Pharm Co., Ltd. remains committed to quality and innovation in the pharmaceutical industry. For more information, please visit hnpoly.com.